Injection of Glatiramer Acetate Depot Results in T1 and T2 Lesion Reduction in Relapsing MS.

Published Date: 01 Mar 2023

Secondary results from a phase 3 study show that patients with multiple sclerosis receiving glatiramer acetate depot therapy have significantly fewer new T1 enhancing lesions and new, enlarging hyperintense T2 lesions.

Read Full News

Latest News


News All Time

Featured News
Featured Articles
Featured Events
Featured KOL Videos

1.

Does diabetes impact the prognosis of people with colorectal cancer?

2.

Is Lenalidomide Resistance in Myeloma Reversible with JAK Inhibition?

3.

Vepdegestrant Earns FDA Nod for ESR1-Mutated Breast Cancer

4.

The need for more Latinx participants in Alzheimer's trials is urgent.

5.

No Gestational Diabetes-Cancer Link; Cholesterol and Cancer; Oncologist Saves Umpire


© Copyright 2026 Hidoc Dr. Inc.

Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation
bot